Excelsior Biopharma (ROCO:6496) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6496 Excelsior Biopharma Inc ROCO:6496
57 GF Score
Price NT$24.00
GF Value NT$34.10
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Excelsior Biopharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:6496
57GF Score
Excelsior Biopharma Inc ROCO:6496
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?

Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued. The current stock price of NT$24.00 is trading 29.6% below its estimated GF Value™ of NT$34.10. GuruFocus considers Excelsior Biopharma to be Modestly Undervalued.

Key valuation signals for ROCO:6496:

  • Dividends Received:
  • GF Value™: NT$34.10 vs. price of NT$24.00 (29.6% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Excelsior Biopharma Business Description

Address Zhongxiao E. Road, 5Floor, No.508, Sector 7, Nangang District, Taipei, TWN, 11561
Excelsior Biopharma Inc. is a Taiwan-based pharmaceutical company engaged in the development, manufacturing, and sale of western medicines and related healthcare products. Its operations span active pharmaceutical ingredient (API) trading and import/export, prescription and generic drug development, pharmaceutical technology transfer, and cooperative research arrangements. The company also markets food products, cosmeceuticals, and cosmetics, and provides technology licensing and development services. Its customer base includes healthcare providers, pharmacies, distributors, and pharmaceutical partners. Geographically, Excelsior Biopharma generates the majority of its revenue from Taiwan, with additional sales in China and other international markets. Revenue is derived from product sales across its pharmaceutical and consumer health lines, as well as from technology transfer and collaborative development agreements with industry partners.
57GF Score

Get the complete analysis for ROCO:6496

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.00
Price
NT$34.10
GF Value